We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+31.61%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$1.19B
AUM Growth
+$204M
Cap. Flow
+$48.2M
Cap. Flow %
4.04%
Top 10 Hldgs %
41.65%
Holding
184
New
58
Increased
50
Reduced
24
Closed
34

Top Buys

Rank Stock Value
1
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22.4M
2
FOLD
Amicus Therapeutics
FOLD
+$14.4M
3
ANIP icon
ANI Pharmaceuticals
ANIP
+$13.8M
4
BLUE
bluebird bio
BLUE
+$11.6M
5
RLYP
RELYPSA INC COM
RLYP
+$11.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$24.3M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$18.9M
3
ARWR icon
Arrowhead Research
ARWR
+$18.4M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$14.7M
5
HCA icon
HCA Healthcare
HCA
+$12.8M

Sector Composition

Rank Sector Weight
1 Healthcare 77.07%
2 Financials 0.1%
3 Energy 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CYH icon
151
Community Health Systems
CYH
$382M
– –
-2,569
Closed -$116K
ELV icon
152
Elevance Health
ELV
$81.5B
– –
-901
Closed -$108K
ENTA icon
153
Enanta Pharmaceuticals
ENTA
$362M
– –
-3,040
Closed -$120K
ICLR icon
154
Icon
ICLR
$13.7B
– –
-2,440
Closed -$140K
ITGR icon
155
Integer Holdings
ITGR
$3.39B
– –
-2,681
Closed -$104K
LGND icon
156
Ligand Pharmaceuticals
LGND
$5.77B
– –
-3,599
Closed -$105K
MCK icon
157
McKesson
MCK
$104B
– –
-527
Closed -$103K
MODV
158
DELISTED
ModivCare
MODV
– –
-2,532
Closed -$122K
PBYI icon
159
Puma Biotechnology
PBYI
$398M
– –
-11,000
Closed -$2.62M
VXRT
160
DELISTED
Vaxart
VXRT
– –
-23,036
Closed -$626K
CMRX
161
DELISTED
Chimerix, Inc.
CMRX
– –
-128,000
Closed -$3.54M
VIRX
162
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,905
Closed -$2.86M
VIRX
163
PUT
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-1,905
Closed -$2.86M
TRVN
164
DELISTED
Trevena, Inc.
TRVN
– –
-1,232
Closed -$4.94M
ABMD
165
DELISTED
Abiomed Inc
ABMD
– –
-25,000
Closed -$789K
AERI
166
DELISTED
Aerie Pharmaceuticals
AERI
– –
-1,121,951
Closed -$5.44M
MGLN
167
DELISTED
Magellan Health Services, Inc.
MGLN
– –
-2,189
Closed -$120K
HRC
168
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-2,657
Closed -$110K
NXTM
169
DELISTED
NxStage Medical Inc.
NXTM
– –
-20,000
Closed -$263K
AMSG
170
DELISTED
Amsurg Corp
AMSG
– –
-2,348
Closed -$118K
AEGR
171
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-366,754
Closed -$12.2M
PTX
172
CALL
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-2,500
Closed -$192K
PCYC
173
DELISTED
PHARMACYCLICS INC
PCYC
– –
-40,000
Closed -$4.7M
ASPX
174
DELISTED
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
– –
-100,000
Closed -$2.57M
GTIV
175
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
– –
-7,052
Closed -$118K
4 5 6
7
8

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Perceptive Advisors held 184 positions worth $1.19B, up 21% from $988M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Perceptive Advisors deployed $48.2M of net new capital in Q4 2014, opening 58 new positions and adding to 50 existing holdings. Its largest new stake was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 80% a quarter earlier, followed by Financials and Energy.

On the sell side, the largest reduction was Celgene Corp, an estimated $24.3M trimmed.

  • Perceptive Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 104,640 shares worth $24.1M.
  • Perceptive Advisors added most to Amicus Therapeutics in Q4 2014, an estimated $14.4M increase.
  • Perceptive Advisors's biggest Q4 2014 reduction was Celgene Corp, cutting an estimated $24.3M.
  • Perceptive Advisors fully exited Arrowhead Research in Q4 2014, selling an estimated $18.4M.
  • Perceptive Advisors's ten largest holdings make up 42% of its $1.19B portfolio in Q4 2014.
  • Perceptive Advisors opened 58 new positions and closed 34 in Q4 2014.
  • Perceptive Advisors's portfolio value rose 21% quarter-over-quarter to $1.19B.

Based on Perceptive Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.